BiomarkersFDA Approvals, News & UpdatesLeukemiaNewsworthy
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL).
FDA Approvals, News & UpdatesNewsworthyGenomic/Genetic Testing
By Dana Taylor
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
Living Beyond Breast Cancer to Host 12th Annual National Metastatic Breast Cancer Conference in Philadelphia, April 20-22
Press Releases – April 10, 2018
Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer.
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
Web Exclusives – April 7, 2018
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
Celebrating Progress and Sharing Hope: The Leukemia & Lymphoma Society to Host Free Rocky Mountain Blood Cancer Conference for Blood Cancer Patients, Survivors and Caregivers
Press Releases – March 25, 2018
The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.
FDA Approvals, News & UpdatesLiver CancerNewsworthy
December 2017 Vol 3 No 6 – December 20, 2017
In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.
Page 3 of 6
Results 21 - 30 of 60
Results 21 - 30 of 60